65,437 trials
Bacteremia
Primary: Number of Participants With One or More Adverse Events (AEs) — 15; 6; 12; 9 Participants
Type 1 Diabetes Mellitus
Primary: The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit — 0.448; 0.350; 0.418 nmol/L — p=0.98
Peripheral Arterial Disease · Vascular Surgery
Primary: Troponin I Elevation Above the Upper Reference Limit (URL) — 25; 22 participants
HIV Infection
Primary: Number of Participants With HIV-1 RNA Response: ≥ 1 Log Decrease in Viral Load — 0 participants
Obesity
Primary: Steady-State AUC of Oseltamivir Carboxylate — 2579 hour*ng/mL
Tendinopathy · Rheumatic Diseases
Primary: Blood Growth Factor Concentrations — 1.078 IGF-1 fold-change from baseline @ 24h
Hand Disinfection
Primary: Microorganisms on Hands Before Scrubbing — 28.99; 38.64; 22.91 colony forming unit
Diabetic Foot Ulcer
Primary: Bacterial Load — -99.9; -50.0 Percent change from baseline
Anaesthesia
Primary: Drug Consumption — 0.0983; 0.1033; 0.0991; 0.0992 mg — p=<0.05
Parkinson Disease · Neurodegenerative Diseases · Central Nervous System Diseases
Primary: Number of Participants Who Experienced at Least One Adverse Event — 123 Participants
Obesity
Primary: Single-dose Serum AUC of Tigecycline Between Time 0 and 96 Hours — 7.64 hour*mg/L
Menopause · Osteoporosis · Osteopenia
Primary: Change From Baseline in Bone Mineral Density — 1.146; 1.132 g/cm2
Multiple Sclerosis
Primary: Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 - Assessment of Global Satisfaction Subscale Score With Teriflunomide Treatment at Week 48 — 68.17…
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 100.0; 100.0; 83.3 percentage of participants